/
Oncology
Nasopharyngeal Carcinoma
87
Pipeline Programs↗
160
Active Trials↗
47
Companies Involved↗
Nasopharyngeal Carcinoma is a moderately active landscape with 87 programs across 47 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., MediLink Therapeutics (Suzhou) Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. 35 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 14
Phase 237
Phase 335
Approved
No programs
Analysis
Modality Breakdown
73%
Small molecule
60 of 82 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 82 classified programs, each share of the total. Modality classified for 99% of 87 pipeline programs.
Analysis
Trial Status
408
clinical trials
Unknown status128 · 31%
Completed98 · 24%
Recruiting81 · 20%
Not yet recruiting44 · 11%
Active, not recruiting34 · 8%
Terminated16 · 4%
Other7 · 2%
Clinical Trials
Trial Activity
408 trials
Induction Chemotherapy Combined With Serplulimab Induction/Maintenance Therapy and Omission of Concurrent Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma (UNION-NPC-001): A Multicenter, Open-Label, Randomized, Controlled, Phase III, Non-Inferiority Clinical Trial
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 3·NCT07177443·710 enrolled
Establishment of "Xijiang Project" Million-Person Screening Cohort for Nasopharyngeal Carcinoma
Recruiting·—·N/A·NCT06787456·1,000,000 enrolled
An Exploratory, Single-arm, Phase II Study of Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
Recruiting·—·Phase 2·NCT07781358·25 enrolled
Page 1 of 28
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)